The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Most Rheumatologists Want FDA to Better Regulate Biosimilars

Most Rheumatologists Want FDA to Better Regulate Biosimilars

July 24, 2015 • By Richard Quinn

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270A new survey from the Coalition of State Rheumatology Organizations (CSRO) has found a majority of rheumatologists are concerned about the safety of biosimilars. The findings add another critical voice to the efforts to ensure that novel treatments are used effectively in the future, according to an ACR committee member.

You Might Also Like
  • Biosimilars Update: FDA Panel Voted to Approve Biosimilars for Etanercept & Adalimumab at July Meeting
  • FDA Proposes Adding Suffixes to Distinguish Biosimilar Drug Names
  • The ACR Addresses the FDA about the Safe Adoption of Biosimilars in the U.S.; Plus Tofacitinib Approved for RA & Romosozumab May Reduce Fracture Risk
Also By This Author
  • Survey Highlights High Out-of-pocket Costs for RA Care

More than 82% of rheumatologists surveyed believe the U.S. Food and Drug Administration (FDA) must set rigorous standards for switching between biosimilar drugs. More than 75% of rheumatologists believe the FDA should make sure biosimilars have a different non-proprietary name than the innovator biologic medicine. And nearly 96% of respondents said the FDA should require labeling to identify a medication as a biosimilar.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Most of the rheumatologists that I know are cautiously optimistic about biosimilars, but really concerned about the safety and efficacy piece,” says Kwas Huston, MD, a member of the ACR’s  Committee on Rheumatologic Care. “The survey demonstrates that there is an overwhelming consensus that we must be vigilant and make sure these drugs are safe.”

In addition to the survey results, CSRO announced policy recommendations on the naming of biosimilars to ensure there’s no confusion with the innovator product and the prominent display on labels of any safety difference between the biologic and its biosimilar. These recommendations closely mirror suggestions the ACR has pushed for regarding safety.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In March, the FDA announced it had approved the first biosimilar drug: the cancer treatment Zarxio. The potential for biosimilars in treating rheumatic diseases is something the ACR supports, but “decisions regarding approval of biosimilars must be driven by sound science,” the ACR’s position paper reads.2

“We require the FDA to provide diligent guidance on how these drugs will be evaluated and approved,” Dr. Huston adds. “I hope the FDA takes that to heart. The only way for biosimilars to enter the market and bring down overall costs [of treatment] is to ensure confidence in the safety and efficacy of these medications.”

Richard Quinn is a freelance writer in New Jersey.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Coalition of State Rheumatology Organizations. News release: CSRO releases physician biosimilars survey results. 2015 July 1.
  2. ACR Committee on Rheumatologic Care. American College of Rheumatology position statement: Biosimilars. February 2015.

Filed Under: Biologics & Biosimilars, Drug Updates, Safety Tagged With: Biologics & Biosimilars, Coalition of State Rheumatology Organizations (CSRO), Drug Safety, Drugs, FDA

You Might Also Like:
  • Biosimilars Update: FDA Panel Voted to Approve Biosimilars for Etanercept & Adalimumab at July Meeting
  • FDA Proposes Adding Suffixes to Distinguish Biosimilar Drug Names
  • The ACR Addresses the FDA about the Safe Adoption of Biosimilars in the U.S.; Plus Tofacitinib Approved for RA & Romosozumab May Reduce Fracture Risk
  • Biosimilars: Unanswered Questions

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)